INSERM-TRANSFERT
Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specializing in technology transfer in life sciences and research funding. It supports the valorization and transfer of research from Inserm laboratories to industry, managing the entire innovation value chain from invention disclosure to industrial partnerships and startups. The company aims to foster long-term collaborations and innovation in human health, with a focus on biomedical research, clinical data, and health databases. It has a strong track record of successful partnerships, patents, and startup support, and actively participates in national and international scientific events and collaborations. Recent initiatives include strategic alliances with major industry players like Sanofi, AstraZeneca, and Almirall, and involvement in European research projects, startups, and innovation ecosystems.
Industries
Nr. of Employees
medium (51-250)
INSERM-TRANSFERT
PariSanté Campus - 10 Rue d'Oradour-sur-Glane - 75015 Paris, France
Patents
Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US-11820726-B2
View DetailsMotuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US-10710957-B2
View Details
Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US-11820726-B2
View DetailsMotuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US-10710957-B2
View DetailsServices
Advisory services covering invention disclosure assessment, commercialization pathway selection and matchmaking with industrial partners.
Assistance with patent strategy, filing preparation and portfolio management to protect research outputs for licensing or spin‑off formation.
Selection, allocation and monitoring of pre‑maturation/proof‑of‑concept grants and seed investments to advance early‑stage technologies.
Structured training and preparatory sessions for researchers considering company creation, including networking and mentorship.
Administrative and scientific project management for multi‑partner national and EU‑funded research projects, including proposal support, consortium coordination and compliance with funder rules.
Design and operational management of long‑term cooperation frameworks with industrial R&D organizations, including joint calls, expert secondments and coordinated thematic actions.
Advisory services covering invention disclosure assessment, commercialization pathway selection and matchmaking with industrial partners.
Assistance with patent strategy, filing preparation and portfolio management to protect research outputs for licensing or spin‑off formation.
Selection, allocation and monitoring of pre‑maturation/proof‑of‑concept grants and seed investments to advance early‑stage technologies.
Structured training and preparatory sessions for researchers considering company creation, including networking and mentorship.
Administrative and scientific project management for multi‑partner national and EU‑funded research projects, including proposal support, consortium coordination and compliance with funder rules.
Design and operational management of long‑term cooperation frameworks with industrial R&D organizations, including joint calls, expert secondments and coordinated thematic actions.
Expertise Areas
- Technology transfer and commercialization
- Intellectual property strategy and patenting
- Pre‑maturation and proof‑of‑concept financing
- Startup creation, acceleration and venture studio support
Key Technologies
- Multi‑omics (transcriptomics, proteomics, metabolomics)
- Biobanking and cohort data management
- AI / machine learning for target discovery and biomarker identification
- Patient‑derived xenograft (PDX) preclinical models
News & Updates
Celebrating 25 years of Inserm Transfert's history and achievements.
A new study reveals a Carmil2 mutation with therapeutic antitumor potential.
Participation in the 10th day of SNITEM on June 17, 2025.
Participation in the BIO International Convention 2025 in Boston.
Participation in the C.U.R.I.E 2025 conference in Bordeaux.
In 2019, Inserm Transfert generated 53.8 million euros in revenue, with significant achievements in patents, startups, and collaborations.
Celebrating 25 years of Inserm Transfert's history and achievements.
A new study reveals a Carmil2 mutation with therapeutic antitumor potential.
Participation in the 10th day of SNITEM on June 17, 2025.
Participation in the BIO International Convention 2025 in Boston.
Participation in the C.U.R.I.E 2025 conference in Bordeaux.
In 2019, Inserm Transfert generated 53.8 million euros in revenue, with significant achievements in patents, startups, and collaborations.